To determine the long-term impact heterozygous loss of EMI1 has on CIN, both EMI1+/− and NT-Control clones were continually passaged for 10 weeks, with serial aliquots assessed by QuantIM every four passages (p; approximately every 2 weeks). This evidence concerns the gene FBXO5 and cervical squamous intraepithelial neoplasia.